The discovery of MTA-uncompetitive PRMT5 inhibitors has galvanized drug discovery efforts to generate precision cancer medicines since MTA is elevated in many cancers due to deletion of MTAP, thereby exposing a synthetic lethal vulnerability. This evidence concerns the gene PRMT5 and cancer.